Mabwell’s innovative CDH17-targeting antibody-drug conjugate, 7MW4911, has received FDA Investigational New Drug (IND) clearance for a Phase 1/2 clinical trial targeting advanced gastrointestinal (GI) cancers, including colorectal cancer. This milestone allows Mabwell to assess the safety, pharmacokinetics, and preliminary efficacy of 7MW4911 in patients with advanced GI tumors, offering a new therapeutic option for a patient population with significant unmet medical needs.
7MW4911, developed using Mabwell’s proprietary IDDC™ platform, leverages the selective delivery of a potent cytotoxic payload to cancer cells expressing cadherin-17 (CDH17), a promising target due to its frequent overexpression in various GI malignancies. The ADC’s structure includes a CDH17 monoclonal antibody (Mab0727), a cleavable linker for precise payload release, and the MF-6 payload, a DNA topoisomerase I inhibitor known for overcoming multidrug resistance and inducing a potent bystander effect, enhancing tumor eradication potential.
Preclinical data supporting the IND clearance demonstrate 7MW4911’s exceptional plasma stability, broad antitumor efficacy across various GI cancers, including challenging genetic profiles like RAS/BRAF mutations, and its ability to overcome multidrug resistance, outperforming established ADC payloads. Moreover, safety assessments indicate limited tissue distribution in animal models and a controllable half-life in cynomolgus monkeys, suggesting a favorable safety profile for human trials.
The upcoming Phase 1/2 clinical trial will evaluate 7MW4911’s safety, tolerability, optimal dosing, and preliminary efficacy in advanced GI cancer patients in the United States, with plans for parallel development in China. This trial marks a significant advancement in targeted therapy development for advanced GI cancers, offering a potential treatment alternative for patients with drug-resistant or difficult-to-treat tumors, addressing a critical unmet need in oncology.
Key Takeaways:
– IND clearance for 7MW4911 enables Mabwell to advance to Phase 1/2 clinical trials targeting advanced GI cancers, addressing significant unmet medical needs.
– The ADC’s unique design and preclinical data supporting broad efficacy, multidrug resistance overcoming capabilities, and favorable safety profile position it as a promising therapeutic candidate for challenging GI malignancies.
– The upcoming clinical trial will provide crucial insights into 7MW4911’s clinical efficacy and safety in advanced GI cancer patients, contributing to the development of targeted therapies for this patient population.
Tags: clinical trials, regulatory
Read more on targetedonc.com